name: MSI-High Colorectal Cancer
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-01-27T02:45:12Z'
description: >-
  Microsatellite instability-high (MSI-H) colorectal cancer is a molecularly defined subtype
  characterized by deficient DNA mismatch repair (dMMR), resulting in hypermutation and high
  tumor mutational burden (TMB). This occurs through germline mutations in MMR genes (Lynch
  syndrome) or sporadic MLH1 promoter hypermethylation. MSI-H tumors have distinct clinical
  features including proximal colon predominance, mucinous histology, and tumor-infiltrating
  lymphocytes. The high neoantigen load makes these tumors exquisitely sensitive to immune
  checkpoint inhibitors, with pembrolizumab now approved as first-line therapy for metastatic
  MSI-H colorectal cancer.
categories:
- Gastrointestinal Cancer
- Colorectal Cancer
- Molecularly Defined Cancer
parents:
- colorectal adenocarcinoma
has_subtypes:
- name: Lynch Syndrome-Associated MSI-H CRC
  description: >-
    Hereditary MSI-H colorectal cancer caused by germline mutations in MMR genes (MLH1, MSH2,
    MSH6, PMS2) or EPCAM deletions affecting MSH2. Accounts for approximately 3% of all CRC.
    Younger age at onset, right-sided predominance, and risk of synchronous/metachronous cancers.
  evidence:
  - reference: PMID:15340260
    supports: PARTIAL
    snippet: >-
      Colorectal cancers resulting from defective DNA mismatch repair can occur in both
      hereditary non-polyposis colon cancer (HNPCC) and in the sporadic setting.
    explanation: >-
      Study confirms that MSI-H colorectal cancers can arise from hereditary (HNPCC/Lynch
      syndrome) or sporadic causes.
- name: Sporadic MSI-H CRC
  description: >-
    Non-hereditary MSI-H colorectal cancer caused by biallelic MLH1 promoter hypermethylation,
    often with concurrent BRAF V600E mutation. Typically occurs in older patients, predominantly
    female, with right-sided tumors.
  evidence:
  - reference: PMID:15340260
    supports: PARTIAL
    snippet: >-
      BRAF mutations were detected in 74% of sporadic tumours but none of the HNPCC
      cancers tested.
    explanation: >-
      Study demonstrates that BRAF mutations distinguish sporadic MSI-H CRC from Lynch
      syndrome-associated tumors.
pathophysiology:
- name: DNA Mismatch Repair Deficiency
  description: >-
    Loss of MMR protein function (MLH1, MSH2, MSH6, or PMS2) impairs the recognition and repair
    of DNA replication errors. The MMR system normally corrects base-base mismatches and
    insertion/deletion loops at microsatellite sequences. Deficiency leads to accumulation of
    thousands of somatic mutations.
  evidence:
  - reference: PMID:41113075
    supports: PARTIAL
    snippet: High microsatellite instability (MSI-H) colorectal cancer (CRC), caused by deficient mismatch repair, 
      accounts for about 15% of all CRC cases and is more common in right-sided tumors.
    explanation: This abstract explicitly links MSI-H CRC to deficient mismatch repair, supporting the core disease 
      mechanism described.
  cell_types:
  - preferred_term: colon epithelial cell
    term:
      id: CL:0011108
      label: colon epithelial cell
  biological_processes:
  - preferred_term: mismatch repair
    modifier: DECREASED
    term:
      id: GO:0006298
      label: mismatch repair
  downstream:
  - target: Microsatellite Instability
    description: Impaired MMR leads to length alterations at microsatellite repeat sequences
  - target: Hypermutation and High TMB
    description: Accumulated replication errors result in high somatic mutation burden
- name: Microsatellite Instability
  description: >-
    Microsatellites are repetitive DNA sequences highly susceptible to replication errors.
    Without functional MMR, these sequences accumulate insertions and deletions, detectable
    as length variations (instability) compared to normal tissue. MSI-H is defined as
    instability at two or more of five standard markers.
  evidence:
  - reference: PMID:36115290
    supports: PARTIAL
    snippet: "Microsatellite unstable (MSI) colorectal cancers (CRCs) are due to DNA mismatch repair (MMR) deficiency"
    explanation: "Abstract links MSI CRC to MMR deficiency, supporting the MSI mechanism."
  locations:
  - preferred_term: colon
    term:
      id: UBERON:0001155
      label: colon
  downstream:
  - target: Frameshift Mutations in Tumor Suppressors
    description: Microsatellite instability causes frameshift mutations in coding sequences
- name: Hypermutation and High TMB
  description: >-
    MSI-H tumors accumulate 10-100 times more somatic mutations than microsatellite stable
    tumors, resulting in tumor mutational burden often exceeding 10-20 mutations per megabase.
    This creates abundant neoantigens derived from mutant peptides presented on MHC molecules.
  evidence:
  - reference: PMID:36115290
    supports: PARTIAL
    snippet: "The pathogenic alterations of MMR genes lead to the accumulation of frequent somatic mutational events"
    explanation: "Abstract notes frequent somatic mutational events from MMR alterations, consistent with hypermutation."
  downstream:
  - target: Neoantigen-Driven Immune Response
    description: High mutation load generates abundant immunogenic neoantigens
- name: Frameshift Mutations in Tumor Suppressors
  description: >-
    Coding microsatellites in tumor suppressor genes (TGFbetaRII, BAX, ACVR2, IGF2R) accumulate
    frameshift mutations, inactivating their tumor suppressive functions. TGFbetaRII frameshift
    is particularly common, disrupting TGF-beta growth inhibition.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
- name: Neoantigen-Driven Immune Response
  description: >-
    The high neoantigen burden in MSI-H tumors stimulates robust anti-tumor immunity.
    Tumor-infiltrating lymphocytes, particularly CD8+ cytotoxic T cells, recognize and
    attack tumor cells presenting neoantigens. However, tumors upregulate PD-L1 as an
    adaptive resistance mechanism.
  cell_types:
  - preferred_term: CD8-positive, alpha-beta T cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: T cell mediated cytotoxicity
    modifier: INCREASED
    term:
      id: GO:0001913
      label: T cell mediated cytotoxicity
  downstream:
  - target: PD-L1 Upregulation and Immune Evasion
    description: Tumors adaptively upregulate checkpoint ligands to suppress T cell attack
- name: PD-L1 Upregulation and Immune Evasion
  description: >-
    MSI-H tumors upregulate PD-L1 expression in response to interferon-gamma from
    infiltrating T cells. PD-L1 engagement of PD-1 on T cells suppresses cytotoxic function,
    allowing immune evasion despite the immunogenic microenvironment. This makes MSI-H
    tumors vulnerable to PD-1/PD-L1 blockade.
histopathology:
- name: Adenocarcinoma
  finding_term:
    preferred_term: Adenocarcinoma
    term:
      id: NCIT:C2852
      label: Adenocarcinoma
  frequency: VERY_FREQUENT
  description: Adenocarcinoma is the most common pathologic subtype of colon cancer.
  evidence:
  - reference: PMID:35613396
    supports: PARTIAL
    snippet: "Adenocarcinoma is the most common pathologic subtype of colon cancer"
    explanation: Abstract reports adenocarcinoma as the most common pathologic subtype of colon cancer.

phenotypes:
- category: Gastrointestinal
  name: Colon Cancer
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    MSI-H colorectal cancer presents as a primary colonic malignancy, with strong right-sided
    (proximal colon) predominance. Tumors often present at earlier stage compared to
    microsatellite stable cancers.
  phenotype_term:
    preferred_term: Colon cancer
    term:
      id: HP:0003003
      label: Colon cancer
- category: Gastrointestinal
  name: Abdominal Pain
  frequency: FREQUENT
  description: >-
    Abdominal discomfort or pain may result from tumor mass effect or partial obstruction,
    particularly with right-sided tumors.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
- category: Gastrointestinal
  name: Hematochezia
  frequency: FREQUENT
  description: >-
    Rectal bleeding may occur, though less prominent than in left-sided colorectal cancers
    due to the proximal location of most MSI-H tumors.
  phenotype_term:
    preferred_term: Hematochezia
    term:
      id: HP:0002573
      label: Hematochezia
- category: Hematologic
  name: Anemia
  frequency: FREQUENT
  description: >-
    Iron deficiency anemia from chronic occult blood loss is common, particularly with
    right-sided tumors where bleeding may not produce visible hematochezia.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
- category: Constitutional
  name: Weight Loss
  frequency: OCCASIONAL
  description: >-
    Unintentional weight loss may occur with advanced disease.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
biochemical:
- name: MSI Testing
  notes: >-
    PCR-based testing of five microsatellite markers (Bethesda panel) or expanded panels.
    MSI-H defined as instability at two or more markers. Next-generation sequencing can
    also detect MSI status.
- name: MMR Immunohistochemistry
  notes: >-
    Immunohistochemistry for MLH1, MSH2, MSH6, and PMS2 proteins. Loss of expression
    indicates MMR deficiency. MLH1/PMS2 loss with concurrent BRAF V600E suggests sporadic
    MSI-H; isolated MSH2/MSH6 loss suggests Lynch syndrome.
- name: Tumor Mutational Burden
  notes: >-
    MSI-H tumors typically have TMB greater than 10 mutations per megabase, often 20-40 mut/Mb.
    High TMB correlates with checkpoint inhibitor response and can be assessed by NGS panels.
genetic:
- name: MLH1
  association: Loss of Function (Somatic or Germline)
  notes: >-
    MLH1 loss occurs via germline mutation (Lynch syndrome) or somatic promoter hypermethylation
    (sporadic). MLH1 hypermethylation accounts for 80% of sporadic MSI-H CRC and is often
    associated with BRAF V600E mutation.
- name: MSH2
  association: Germline Loss of Function
  notes: >-
    MSH2 germline mutations are the second most common cause of Lynch syndrome. EPCAM deletions
    can also cause MSH2 silencing through promoter methylation.
- name: MSH6
  association: Germline Loss of Function
  notes: >-
    MSH6 germline mutations cause Lynch syndrome with attenuated phenotype and later age of onset.
- name: PMS2
  association: Germline Loss of Function
  notes: >-
    PMS2 germline mutations cause Lynch syndrome with lower penetrance than MLH1/MSH2 mutations.
- name: BRAF V600E
  association: Somatic Activating Mutation (Sporadic MSI-H)
  notes: >-
    BRAF V600E is present in approximately 40-50% of sporadic MSI-H CRC, virtually always
    with MLH1 hypermethylation. Its presence excludes Lynch syndrome. Unlike MSS BRAF-mutant
    CRC, MSI-H BRAF-mutant tumors respond well to checkpoint inhibitors.
treatments:
- name: Pembrolizumab
  description: >-
    Anti-PD-1 immune checkpoint inhibitor approved as first-line monotherapy for metastatic
    MSI-H/dMMR colorectal cancer. KEYNOTE-177 demonstrated superior progression-free survival
    compared to chemotherapy with durable responses in a subset of patients.
  evidence:
  - reference: PMID:33264544
    supports: SUPPORT
    snippet: "Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer"
    explanation: "KEYNOTE-177 abstract reports improved progression-free survival with first-line pembrolizumab versus chemotherapy."
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Nivolumab plus Ipilimumab
  description: >-
    Combination checkpoint blockade with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab)
    approved for MSI-H/dMMR metastatic CRC. CheckMate 142 showed high response rates and
    durable disease control with combined checkpoint inhibition.
  evidence:
  - reference: PMID:29355075
    supports: SUPPORT
    snippet: >-
      investigator-assessed ORR was 55% (95% CI, 45.2 to 63.8), and disease control
      rate for â‰¥ 12 weeks was 80%
    explanation: >-
      CheckMate-142 trial demonstrated high objective response rate (55%) and disease
      control rate (80%) with nivolumab plus ipilimumab in dMMR/MSI-H mCRC.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Dostarlimab
  description: >-
    Anti-PD-1 antibody with remarkable activity in MSI-H rectal cancer. A single-arm study
    demonstrated 100% clinical complete response rate in locally advanced MSI-H rectal cancer,
    allowing organ preservation without surgery or radiation.
  evidence:
  - reference: PMID:35660797
    supports: PARTIAL
    snippet: >-
      All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete
      response, with no evidence of tumor on magnetic resonance imaging,
      18F-fluorodeoxyglucose-positron-emission tomography, endoscopic evaluation,
      digital rectal examination, or biopsy.
    explanation: >-
      Phase 2 study showed 100% clinical complete response rate with dostarlimab
      monotherapy in mismatch repair-deficient locally advanced rectal cancer.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Surgical Resection
  description: >-
    Surgery remains the primary curative treatment for localized MSI-H colorectal cancer.
    Patients with Lynch syndrome may benefit from extended colectomy due to risk of
    metachronous tumors.
  evidence:
  - reference: PMID:35660797
    supports: PARTIAL
    snippet: >-
      Neoadjuvant chemotherapy and radiation followed by surgical resection of the
      rectum is a standard treatment for locally advanced rectal cancer.
    explanation: >-
      The study confirms surgical resection is standard treatment for locally advanced
      rectal cancer, supporting the role of surgery in MSI-H CRC.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
disease_term:
  preferred_term: MSI-high colorectal cancer
  term:
    id: MONDO:0005575
    label: colorectal cancer

classifications:
  icdo_morphology:
    classification_value: Adenocarcinoma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: solid tumor
